Immunic (IMUX) – Research Analysts’ Weekly Ratings Updates

Immunic (NASDAQ: IMUX) recently received a number of ratings updates from brokerages and research firms:

  • 9/10/2019 – Immunic was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis and psoriasis. The company’s product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. “
  • 9/6/2019 – Immunic was given a new $40.00 price target on by analysts at Chardan Capital. They now have a “buy” rating on the stock.
  • 8/31/2019 – Immunic was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis and psoriasis. The company’s product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. “
  • 8/24/2019 – Immunic was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis and psoriasis. The company’s product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. “
  • 8/17/2019 – Immunic was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis and psoriasis. The company’s product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. “
  • 8/12/2019 – Immunic is now covered by analysts at Chardan Capital. They set a “buy” rating and a $40.00 price target on the stock. They wrote, “We see this trial as potentially supportive of an accelerated path to approval/market for IMU-838, as PSC is an orphan indication, which may provide earlier revenues and/or help derisk testing of IMU-883 in larger market indications.””
  • 8/1/2019 – Immunic was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.

NASDAQ IMUX traded up $0.51 during trading on Friday, reaching $14.25. 1,274 shares of the stock traded hands, compared to its average volume of 35,909. The company has a market capitalization of $15.25 million, a price-to-earnings ratio of -0.40 and a beta of 3.59. The firm’s 50-day moving average is $13.91. Immunic has a fifty-two week low of $6.00 and a fifty-two week high of $46.80.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.80). On average, research analysts expect that Immunic will post -3.78 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. acquired a new position in Immunic during the second quarter valued at approximately $132,000. Tower Research Capital LLC TRC bought a new position in Immunic in the second quarter valued at approximately $33,000. BlackRock Inc. bought a new position in Immunic in the second quarter valued at approximately $145,000. Omega Fund Management LLC bought a new position in Immunic in the second quarter valued at approximately $15,731,000. Finally, Independent Advisor Alliance bought a new position in Immunic in the second quarter valued at approximately $804,000.

Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.

Recommended Story: How To Calculate Debt-to-Equity Ratio

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.